Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Targeted Drug ALK Inhibitors for NSCLC market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Targeted Drug ALK Inhibitors for NSCLCmarket, defines the market attractiveness level of Targeted Drug ALK Inhibitors for NSCLC market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Targeted Drug ALK Inhibitors for NSCLC industry, describes the types of Targeted Drug ALK Inhibitors for NSCLC market, the applications of major players and the market size, and deeply analyzes the current situation of the global Targeted Drug ALK Inhibitors for NSCLC market and the development prospects and opportunities of Targeted Drug ALK Inhibitors for NSCLC industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Targeted Drug ALK Inhibitors for NSCLC market in Chapter 13.
By Player:
Incepta Pharmaceuticals
Chugai Pharmaceutical (Hoffmann-La Roche group)
Beacon Pharma Limited
Genvio Pharma Limited
Drug International Limted
Pfizer
ARIAD Pharmaceuticals (Takeda)
Novartis
By Type:
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
By End-User:
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Targeted Drug ALK Inhibitors for NSCLC Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Targeted Drug ALK Inhibitors for NSCLC Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Targeted Drug ALK Inhibitors for NSCLC Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Targeted Drug ALK Inhibitors for NSCLC Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Targeted Drug ALK Inhibitors for NSCLC Market Analysis and Outlook to 2022
-
7.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.2 United States Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.4 China Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.5 Japan Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.6 India Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
-
7.7 South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption (2017-2022)
8 Region and Country-wise Targeted Drug ALK Inhibitors for NSCLC Market Analysis and Outlook to 2028
-
8.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.2 United States Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.3 Europe Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.4 China Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.5 Japan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.6 India Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
-
8.7 South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast (2022-2028)
9 Global Targeted Drug ALK Inhibitors for NSCLC Market Outlook by Types and Applications to 2022
-
9.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Crizotinib Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Ceritinib Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Alectinib Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Brigatinib Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Lorlatinib Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
10 Global Targeted Drug ALK Inhibitors for NSCLC Market Outlook by Types and Applications to 2028
-
10.1 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Ceritinib Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Alectinib Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Lorlatinib Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
11 Global Targeted Drug ALK Inhibitors for NSCLC Import and Export Analysis (Top 5 Countries)
-
11.1 Global Targeted Drug ALK Inhibitors for NSCLC Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Targeted Drug ALK Inhibitors for NSCLC Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Targeted Drug ALK Inhibitors for NSCLC Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Targeted Drug ALK Inhibitors for NSCLC Market Competitive Analysis
-
14.1 Incepta Pharmaceuticals
-
14.1.1 Incepta Pharmaceuticals Company Details
-
14.1.2 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.2 Chugai Pharmaceutical (Hoffmann-La Roche group)
-
14.2.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
-
14.2.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.3 Beacon Pharma Limited
-
14.3.1 Beacon Pharma Limited Company Details
-
14.3.2 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.4 Genvio Pharma Limited
-
14.4.1 Genvio Pharma Limited Company Details
-
14.4.2 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.5 Drug International Limted
-
14.5.1 Drug International Limted Company Details
-
14.5.2 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.6 Pfizer
-
14.6.1 Pfizer Company Details
-
14.6.2 Pfizer Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.7 ARIAD Pharmaceuticals (Takeda)
-
14.7.1 ARIAD Pharmaceuticals (Takeda) Company Details
-
14.7.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
14.8 Novartis
-
14.8.1 Novartis Company Details
-
14.8.2 Novartis Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Targeted Drug ALK Inhibitors for NSCLC
-
Figure Targeted Drug ALK Inhibitors for NSCLC Picture
-
Table Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Consumption by Country (2017-2022)
-
Figure United States Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Table Europe Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure China Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Japan Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure India Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast by Country (2022-2028)
-
Figure United States Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Targeted Drug ALK Inhibitors for NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Crizotinib Consumption and Growth Rate (2017-2022)
-
Figure Global Ceritinib Consumption and Growth Rate (2017-2022)
-
Figure Global Alectinib Consumption and Growth Rate (2017-2022)
-
Figure Global Brigatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Lorlatinib Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Adenocarcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption and Growth Rate (2017-2022)
-
Figure Global Crizotinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ceritinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alectinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Brigatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Lorlatinib Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Squamous Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Adenocarcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Large Cell Carcinoma of NSCLC Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Targeted Drug ALK Inhibitors for NSCLC Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Targeted Drug ALK Inhibitors for NSCLC Export by Region (Top 5 Countries) (2017-2028)
-
Table Incepta Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) (Foundation Year, Company Profile and etc.)
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Beacon Pharma Limited (Foundation Year, Company Profile and etc.)
-
Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Genvio Pharma Limited (Foundation Year, Company Profile and etc.)
-
Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Drug International Limted (Foundation Year, Company Profile and etc.)
-
Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table ARIAD Pharmaceuticals (Takeda) (Foundation Year, Company Profile and etc.)
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Targeted Drug ALK Inhibitors for NSCLC Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Service
-
